Newron is discussing the FDA clinical hold and safety concerns in its ENIGMA-TRS treatment-resistant schizophrenia program. For $NWPHF, the hold is the whole story — until there’s a clear path forward

FDA clinical hold and safety concerns in schizophrenia program drive high-priority biotech alert.